Abbott Laboratories (NYSE:ABT) Stock Price Target Cut by TD Cowen

Abbott Laboratories (NYSE:ABT) had its target price cut by investment analysts at TD Cowen from $135.00 to $118.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the healthcare product maker’s stock. TD Cowen’s price objective would indicate a potential upside of 17.04% from the company’s current price.

Other research analysts also recently issued research reports about the stock. UBS Group decreased their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Robert W. Baird lifted their price target on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday. Weiss Ratings raised Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Finally, Barclays started coverage on Abbott Laboratories in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $117.92.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $100.82 on Thursday. The stock has a 50 day moving average price of $105.47 and a 200 day moving average price of $98.28. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock has a market capitalization of $174.46 billion, a PE ratio of 32.58, a price-to-earnings-growth ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. During the same quarter in the prior year, the business posted $1.30 EPS. The business’s revenue was up 14.5% compared to the same quarter last year. Analysts predict that Abbott Laboratories will post 5.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ledyard National Bank grew its stake in shares of Abbott Laboratories by 6.4% in the third quarter. Ledyard National Bank now owns 15,237 shares of the healthcare product maker’s stock valued at $1,506,000 after acquiring an additional 913 shares in the last quarter. Culbertson A N & Co. Inc. raised its stake in Abbott Laboratories by 0.3% in the 3rd quarter. Culbertson A N & Co. Inc. now owns 90,195 shares of the healthcare product maker’s stock worth $8,914,000 after purchasing an additional 270 shares in the last quarter. NBT Bank N.A. bought a new stake in Abbott Laboratories in the 3rd quarter valued at about $9,060,000. Root Financial Partners LLC grew its position in shares of Abbott Laboratories by 93.7% during the 3rd quarter. Root Financial Partners LLC now owns 7,430 shares of the healthcare product maker’s stock worth $734,000 after purchasing an additional 3,594 shares in the last quarter. Finally, Precedent Wealth Partners LLC grew its position in shares of Abbott Laboratories by 10.7% during the 3rd quarter. Precedent Wealth Partners LLC now owns 33,354 shares of the healthcare product maker’s stock worth $3,296,000 after purchasing an additional 3,234 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, in line with the broader consensus, while revenue of $13.01 billion slightly exceeded the $12.99 billion estimate. Reported sales increased 14.5% year over year, and comparable sales rose 7%. Abbott Reports Third-Quarter 2026 Results
• Positive Sentiment: The company reaffirmed its full-year adjusted EPS guidance, while highlighting new product approvals and margin expansion. The results also showed year-over-year EPS growth from $1.30 to $1.42. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Robert W. Baird raised its ABT price target from $121 to $123 and maintained an “outperform” rating. BTIG lowered its target from $134 to $125 but retained a “buy” rating; both targets imply substantial upside from the reference price. Benzinga Analyst Actions
• Neutral Sentiment: Abbott intends to execute a tax-free spin-off of its approximately $8.5 billion Nutrition business, including Similac, Ensure and Pedialyte, by the end of 2027. Management expects the separation to sharpen strategic focus and improve Abbott’s growth and margin profile, but investors must assess execution and the eventual standalone businesses. Abbott Nutrition Spin-Off Announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth forecast, citing weakness in medical devices. That outlook revision overshadowed the revenue beat and raised concerns about near-term momentum. Abbott Lowers 2026 Sales Growth Forecast
• Negative Sentiment: Some analysts characterized adjusted EPS as a modest miss against a $1.43 estimate, adding to the cautious reaction. The Nutrition separation also introduced uncertainty and contributed to selling pressure despite strong headline growth. ABT Stock Down After Third-Quarter Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.